Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FLT3 exon 14 ins FLT3 F691L |
| Therapy | Tuspetinib |
| Indication/Tumor Type | hematologic cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FLT3 exon 14 ins FLT3 F691L | hematologic cancer | predicted - sensitive | Tuspetinib | Preclinical | Actionable | In a preclinical study, Tuspetinib (HM43239) treatment inhibited transformed cells expressing FLT3 ITD and F691L in cell culture (Cancer Res 2019;79(13 Suppl):Abstract nr 1293). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| HM43239, a novel FLT3 inhibitor in overcoming resistance for acute myeloid leukemia | Full reference... |